Abstract:Previous studies have demonstrated that microRNA (miR)-146a is involved in the inflammatory response of atopic dermatitis (AD). The aim of the present study was to investigate the expression of miR-146a in the serum of patients with AD and in skin lesions of AD animal models. In addition, we aimed to predict and verify the target genes of miR-146a. miR-146a expression was measured in AD patient serum via reverse transcription-quantitative PCR. T-helper (Th)1 [CD4(+); interferon (IFN)-gamma(+)] and Th2 [CD4(+); interleukin (IL)-4(+)] expression in peripheral blood mononuclear cells was evaluated using flow cytometry. Following the establishment of a 2,4-dinitrofluorobenzene-induced C57BL/6 mouse AD model, Th1 (CD4(+)IFN-gamma(+)) and Th2 (CD4(+)IL-4(+)) expression was analyzed in murine spleen cells via flow cytometry. Plasmids were transfected into 293T cells and at 48 h post-transfection, cells were analyzed using a luciferase assay system. The results revealed that the AD group had a significantly lower Th1/Th2 ratio and a significantly higher miR-146a expression compared with the control group (P<0.05). Furthermore, a decreased Th1/Th2 ratio and a significantly increased miR-146a expression were observed in the model group compared with the control group (P<0.01). We also conducted a dual-luciferase assay to determine whether small ubiquitin-related modifier 1 (SUMO1) if the target gene of miR-146a. We observed a similar to 30% decrease in the relative luciferase activity in cells containing the 3 '-untranslated region of SUMO1 + miR-146a). The results of the luciferase assay indicated that may be a direct mRNA target of miR-146a; however, the quantification of band density of SUMO1 expression following western blotting did not significantly differ. The development of animal models in AD research is of vital importance. The results revealed that miR-146a may be a potential regulator involved in the pathogenesis of AD. Furthermore, the current study determined that miR-146a could be a valuable marker of AD and thus, may be applied in the development of therapeutic strategies for treating AD.

MicroRNA-146a in related dermatoses

MicroRNA-146a and Human Disease

Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment.

MicroRNA‑146a As a Potential Regulator Involved in the Pathogenesis of Atopic Dermatitis.

Function of Microrna-145 and Mechanisms Underlying Its Role in Malignant Tumor Diagnosis and Treatment

Advances in the function and target genes of miR-146a

MicroRNAs in Human Diseases: From Autoimmune Diseases to Skin, Psychiatric and Neurodegenerative Diseases

The Role of MicroRNAs in Autoimmune Diseases with Skin Involvement

MiR-146 in immunity and autoimmune diseases

MicroRNAs in Atopic Dermatitis: A Systematic Review

MicroRNA-146a Signature in Psoriasis: A Systematic Review and Meta-Analysis

The Essential Role of microRNAs in Inflammatory and Autoimmune Skin Diseases—A Review

MicroRNA-146a and hemopoietic disorders

Control by a hair’s breadth: the role of microRNAs in the skin

MicroRNAs: Emerging Players in the Pathogenesis of Vitiligo

Analysis of the Expression Profile of Mirnas Related to Skin Photoaging in the GEO Database

Roles of Micrornas in Psoriasis: Immunological Functions and Potential Biomarkers

MiR‐151a is Involved in the Pathogenesis of Atopic Dermatitis by Regulating Interleukin‐12 Receptor Β2

Recent progress in studies of miRNA and skin diseases

Targeting microRNA for improved skin health

A SINGLE-NUCLEOTIDE OF POLYMORPHISM OF PRE-miR-146a AND PSORIASIS: AN ASSOCIATION AND FUNCTIONAL STUDY